Results 181 to 190 of about 591,059 (370)

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Benign Peritoneal and Retroperitoneal Neoplasm [PDF]

, 2020
openaire   +1 more source

Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms [PDF]

Nazim Benzerdjeb, P. Dartigues, Vahan Képénékian, Francesca Damiola, Ruth Sequeiros, Françoise Galateau-Sallé, H. Begueret, Eliane Mery-Lamarche, Diane Damotte, Véronique Verrièle, J. Fontaine, S. Isaac, Séverine Valmary‐Degano, Laurent Villeneuve, Olivier Gléhen, A. Scherpereel, Fabien Forest, A. de la Fourchardière, Sandrine Paindavoine, A. Hourlier, Daniel Pissaloux, Franck Tirode, Sylvie Lantuéjoul   +22 more
openalex   +1 more source

Retrospective Review of Outcomes in Non-Invasive Mucinous Appendiceal Neoplasms with and without Peritoneal Spread: A Cohort Study [PDF]

, 2022
Arkadii Sipok, Jonathan Dort, Anthony Visioni, Lana Bijelić   +3 more
openalex   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, EarlyView.
What's New? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits

Annals of Surgical Oncology, 2018
C. Roxburgh, Y. Fenig, A. Cercek, J. Shia, Rachel M. Rassam, P. Paty, G. Nash   +6 more
semanticscholar   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, EarlyView.
What's New? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Total pelvic exenterative surgery in patients with peritoneal metastases from appendiceal neoplasms. A case series of 2 patients

, 2019
Paul H. Sugarbaker
openalex   +1 more source

Mixed Neuroendocrine-Non Neuroendocrine Neoplasms (MiNEN) of the Appendix Presenting with Signs and Symptoms of Small Bowel Obstruction and Gnarly Implants in the Peritoneal Cavity, but no Ascites

, 2020
Tsigani Elena Geladari Eleni
openalex   +1 more source

Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis

International Journal of Cancer, EarlyView.
What's New? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin, Li Zhu, Yuyang Huang, Lizhu Chen, Yuping Lu, Yu Chen, Jing Lin   +6 more
wiley   +1 more source